• Citer

Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum - An adjuvant to antiretroviral tritherapy

par Zagury, Daniel;Lecoq, H.;Gervi, I.;Le Buanec, Hélène ;Zagury, Jean-François;Bizzini, Bernard;Burny, Arsène ;Hermans, Philippe ;Perja, Muça;Santagostino, Elena;Gringeri, Alessandro
Référence Biomedicine & pharmacotherapy, 53, 2, page (90-92)
Publication Publié, 1999-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV- 1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFNα vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFNα Abs (whether under HAART or not) when compared to placebo or non- responder vaccinees, a strong correlation was found between an increased IFNα neutralizing capacity and the reduction of clinical manifestations.